The stem cell clinic business US Stem Cell Inc., formerly known as Bioheart, has seen its stock take a rollercoaster ride recently include a big run up and now today a big drop so what’s the scoop? US Stem Cell, which includes a few subsidiaries such as US Stem Cell Clinic, focuses on the use […]
What’s the deal with US Stem Cell Inc stock? Read More »
What’s the deal with Trump’s HHS Secretary pick Rep. Tom Price (now testifying before the Senate) and the amniotic tissue/stem cell company MiMedx that’s caused some buzz in the last 48 hours? I’ve been following MiMedx for a few years since it received an untitled letter from the FDA and I noted its claim of one its
Tom Price & MiMedx: a stem cell connection? Read More »
What happens for patients and clinics after a stem cell facelift gone wrong? What about other cell injection problems? Cell therapies raise new challenges and risks. You can stop taking a pill or an injection treatment. However, you can’t stop or retract stem cell treatments if there’s a bad side effect. Unlike other kinds of
Clinics can’t retract problems like stem cell facelift gone wrong Read More »
Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions.
Stem Cell Predictions for 2017 Read More »
Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions,
Grading my stem cell predictions for 2016: how’d I do? Read More »
San Diego-based stem cell business Stemgenex is the subject of a suit over allegations about stem cell treatments. The company has now filed a motion to dismiss the case. To me as a non-attorney, the Stemgenex motion to dismiss seems to emphasize overall vagueness of the plaintiff’s case and argues in part that there is insufficient detailed support of each claim. From
Stemgenex motion to dismiss aims to rebut stem cell suit claims Read More »
The money behind a piece of legislation can provide unique insights into the back story and this is definitely true for the REGROW Act that would reduce FDA oversight of the investigational use of stem cells in patients. Senator Mark Kirk of Illinois, who is facing probable defeat next week in his reelection bid according to
REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises Read More »
Each December I make stem cell predictions for the coming year and I did that for 2016 where I made 20 predictions. At around mid year I do a checkup on how my predictions are doing halfway and that is the purpose of this post. Below are my predictions that I made in 2015 for stem
Stem cell checkup: how are my 2016 predictions doing half way? Read More »
A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for
End of line for StemCells Inc., pioneering & controversial stem cell biotech Read More »
Four or five years ago the top stem cell story was the battle over federal funding of human embryonic stem (ES) cell research in the U.S. by James Sherley and Theresa Deisher. They were the two opponents of ES cell research making the most national headlines. Nature did a whole piece back then on Deisher
Where are ES cell foes James Sherley & Theresa Deisher now? Read More »